Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Toxicon X
2019 Feb 23;2:100010. doi: 10.1016/j.toxcx.2019.100010.
Show Gene links
Show Anatomy links
Fluorescent analogues of BeKm-1 with high and specific activity against the hERG channel.
Vasseur L
,
Chavanieu A
,
Combemale S
,
Caumes C
,
Béroud R
,
De Waard M
,
Ducrot P
,
Boutin JA
,
Ferry G
,
Cens T
.
???displayArticle.abstract???
Peptidic toxins that target specifically mammalian channels and receptors can be found in the venom of animals. These toxins are rarely used directly as tools for biochemical experiments, and need to be modified via the attachment of chemical groups (e.g., radioactive or fluorescent moieties). Ideally, such modifications should maintain the toxin specificity and affinity for its target. With the goal of obtaining fluorescent derivatives of BeKm-1, a toxin from the scorpion species Buthus eupeus that selectively inhibits the voltage-gated potassium ion channel hERG, we produced four active analogues using a model of BeKm-1 docking to the outer mouth of the channel. In these BeKm-1 analogues, the natural peptide was linked to the fluorescent cyanine 5 (Cy5) probe via four different linkers at Arg1 or Arg/Lys27. All analogues retained their specificity towards the hERG channel in electrophysiological experiments but displayed a lesser affinity. These results validate our strategy for designing toxin analogues and demonstrate that different chemical groups can be attached to different residues of BeKm-1.
Fig. 1. Docking of BeKm-1 in a model of hERG channel and fluorescent BeKm-1 analogues used in this study. A) Left, BeKm-1 (pdb code: 1j5, magenta, top) in interaction with hERG channel (in solid ribbon representation showing the solvent surface colored by hydrophobicity). The tetrameric model of the hERG channel was generated from the pdb structure (5VA1) using the Prepare Protein module within Discovery Studio. The transmembrane domain, the cytoplasmic N-terminal Per-Arnt-Sim (PAS) domain, the C-terminal C-linker and the cyclic nucleotide binding domain (CNBD) are indicated. Docking of BeKm-1 was performed using the ZDOCK rigid body docking program and refined with the RDOCK module. The top ranked pose of the most populated cluster from the protein-protein interaction predictions is showed with BeKm-1 docked at the top of the transmembrane domain of hERG. Right, Details of the pose of BeKm-1 (magenta) within the interaction surface of hERG colored according to the Solvent Accessibility Surface (SAS) (see Supplementary Data S2), with the side chain of the N terminal Arg1 and Arg27 (red) and the more buried C terminal Phe36 (orange). B) Chemical structures of fluorescent BeKm-1 analogues used in this study with different types of linkers grafted on the N-ter of Arg1 or the side chain of Arg27 mutated for a Lysine. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
Fig. 2. The fluorescent BeKm-1 analogues potently inhibit hERG currents. A) Typical traces of currents recorded in Xenopus laevis oocytes that express hERG. Currents were elicited using the protocol depicted at the top in which a pulse from a holding potential of −80 mV to −30 mV precedes a test pulse at −50 mV, in the presence of increasing concentrations of native BeKm-1, Cy5-PEG3-linker4-BeKm-1, Cy5-spacerGS-linker6-BeKm-1, Cy5-PEG5-linker10-BeKm-1 or Cy5-PEG5-BeKm1-Lys27. Scale bars, 200 nA. B) Inhibition curves of native BeKm-1 and its four analogues. The peak current amplitude was measured during the test pulse at −50 mV in the presence of toxin (ITx) and normalized to the current recorded in the absence of toxin (ICt). Data are the mean ± SEM of n = 4–10 oocytes.
Fig. 3. The fluorescent BeKm-1 analogues do not affect hKv10.1 and hKv1.3 currents. A) Typical traces of currents elicited by a step depolarization to 0 mV or 70 mV, from a holding potential of −80 mV, obtained from Xenopus laevis oocytes that express hKv10.1 or hKv1.3, respectively, in the absence or presence of 200 nM native BeKm-1 and in the absence or presence of 500 nM of Cy5-PEG3-linker4-BeKm-1, of Cy5-spacerGS-linker6-BeKm-1, of Cy5-PEG5-linker10-BeKm-1 and of Cy5-PEG5-BeKm1-Lys27. Note the lack of effect of BeKm-1 and of the four analogues on both channels. B) Percentage of current remaining in the presence of a single dose of native BeKm-1 or its four analogues (Cy5-PEG3-linker4-BeKm-1, Cy5-spacerGS-linker6-BeKm-1, Cy5-PEG5-linker10-BeKm-1 and Cy5-PEG5-BeKm1-Lys27). Current amplitude was measured before (ICt) and during (Itx) the perfusion of the different toxins. Data are the mean ± SEM of n = 4–7 oocytes.
Fig. 4. The mutation S631C in hERG decreases the affinity of native BeKm-1 and of its four fluorescent analogues for the channel. Comparison of the inhibition curves of native BeKm-1 and its four analogues Cy5-PEG3-linker4-BeKm-1, Cy5-spacerGS-linker6-BeKm-1, Cy5-PEG5-linker10-BeKm-1 and Cy5-PEG5-BeKm1-Lys27 obtained in Xenopus laevis oocytes that express wild type (WT) hERG or the mutant S631C. The data obtained with the mutant channel were fitted by hand for the purpose of comparison. Data are the mean ± SEM of n = 3–5 oocytes.
Angelo,
A radiolabeled peptide ligand of the hERG channel, [125I]-BeKm-1.
2003, Pubmed
Angelo,
A radiolabeled peptide ligand of the hERG channel, [125I]-BeKm-1.
2003,
Pubmed
Beeton,
Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases.
2006,
Pubmed
Bergeron,
Scorpion toxins specific for potassium (K+) channels: a historical overview of peptide bioengineering.
2012,
Pubmed
Boutin,
[Cryo-microscopy, an alternative to the X-ray crystallography?].
,
Pubmed
Chandy,
Peptide blockers of Kv1.3 channels in T cells as therapeutics for autoimmune disease.
2017,
Pubmed
Chiu,
Validation of a [3H]astemizole binding assay in HEK293 cells expressing HERG K+ channels.
2004,
Pubmed
Finlayson,
[3H]dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen.
2001,
Pubmed
Hancox,
The hERG potassium channel and hERG screening for drug-induced torsades de pointes.
2008,
Pubmed
Hausammann,
Chimeric hERG channels containing a tetramerization domain are functional and stable.
2013,
Pubmed
,
Xenbase
Housley,
Scorpion toxin peptide action at the ion channel subunit level.
2017,
Pubmed
Korolkova,
An ERG channel inhibitor from the scorpion Buthus eupeus.
2001,
Pubmed
Korolkova,
Unique interaction of scorpion toxins with the hERG channel.
2004,
Pubmed
Korolkova,
New binding site on common molecular scaffold provides HERG channel specificity of scorpion toxin BeKm-1.
2002,
Pubmed
Kuzmenkov,
Fluorescent protein-scorpion toxin chimera is a convenient molecular tool for studies of potassium channels.
2016,
Pubmed
,
Xenbase
Lastraioli,
hERG1 Potassium Channels: Novel Biomarkers in Human Solid Cancers.
2015,
Pubmed
Milnes,
Preferential closed channel blockade of HERG potassium currents by chemically synthesised BeKm-1 scorpion toxin.
2003,
Pubmed
Schembri,
Synthesis, Biological Evaluation, and Utility of Fluorescent Ligands Targeting the μ-Opioid Receptor.
2015,
Pubmed
Tarcha,
Safety and pharmacodynamics of dalazatide, a Kv1.3 channel inhibitor, in the treatment of plaque psoriasis: A randomized phase 1b trial.
2017,
Pubmed
Tseng,
Probing the outer mouth structure of the HERG channel with peptide toxin footprinting and molecular modeling.
2007,
Pubmed
,
Xenbase
Uysal,
Crystal structure of full-length KcsA in its closed conformation.
2009,
Pubmed
Vandenberg,
hERG K(+) channels: structure, function, and clinical significance.
2012,
Pubmed
Wang,
Cryo-EM Structure of the Open Human Ether-à-go-go-Related K+ Channel hERG.
2017,
Pubmed
Whicher,
Structure of the voltage-gated K⁺ channel Eag1 reveals an alternative voltage sensing mechanism.
2016,
Pubmed
Zhang,
BeKm-1 is a HERG-specific toxin that shares the structure with ChTx but the mechanism of action with ErgTx1.
2003,
Pubmed
,
Xenbase
de Souza,
Animal Toxins as Therapeutic Tools to Treat Neurodegenerative Diseases.
2018,
Pubmed